Evaluation of the Zilver® Vena™ Venous Stent (VIVO EU)
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Contacts and Locations
Study Locations
-
-
-
Arnsberg, Germany
- Klinikum Arnsberg GmbH
-
-
-
-
-
Galway, Ireland
- Galway University Hospitals
-
-
-
-
-
Madrid, Spain
- Hospital Madrid Montepríncipe
-
-
-
-
-
Winterthur, Switzerland, 8401
- Kantonsspital Winterthur
-
-
-
-
-
London, United Kingdom, SE1 7EH
- Guy's and St Thomas' Hospital
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Symptomatic venous outflow obstruction in up to two iliofemoral venous segments (one in each limb), demonstrated by:
- CEAP 'C' ≥ 3, or
- VCSS pain score ≥ 2
Exclusion Criteria:
- < 18 years of age
- Pregnant or planning to become pregnant in the next 12 months
- Planned surgical or interventional procedures (except thrombolysis and thrombectomy in preparation for the procedure or vena cava filter placement prior to stent implantation in patients at high risk for pulmonary embolism) within 30 days prior to or after the study procedure.
- Lesions with intended treatment lengths extending into the inferior vena cava or below the level of the lesser trochanter
- Previous stenting of the target vessel
- Iliofemoral venous segment unsuitable for treatment with available sizes of study devices
Study Plan
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Prospective
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Stent
|
Stenting iliofemoral venous outflow obstruction
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Major Adverse Events
Time Frame: 1 month
|
1 month
|
|
|
Patency
Time Frame: 12 months
|
Assessed via ultrasound
|
12 months
|
Collaborators and Investigators
Sponsor
Sponsor
Publications and helpful links
General Publications
- O'Sullivan GJ, Waldron D, Mannion E, Keane M, Donnellan PP. Thrombolysis and iliofemoral vein stent placement in cancer patients with lower extremity swelling attributed to lymphedema. J Vasc Interv Radiol. 2015 Jan;26(1):39-45. doi: 10.1016/j.jvir.2014.10.010.
- O'Sullivan GJ, Sheehan J, Lohan D, McCann-Brown JA. Iliofemoral venous stenting extending into the femoral region: initial clinical experience with the purpose-designed Zilver Vena stent. J Cardiovasc Surg (Torino). 2013 Apr;54(2):255-61.
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
Other Study ID Numbers
- 10-018
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.